Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Lou F. M. H. de Leij"'
Autor:
Marcel H. J. Ruiters, Lieuwe J. Melchers, Lou F. M. H. de Leij, Marianne G. Rots, Pamela M.J. McLaughlin, Bernardina T. F. van der Gun
Publikováno v:
CARCINOGENESIS. 31(11):1913-1921
The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that is highly expressed on most carcinomas and therefore of potential use as a diagnostic and prognostic marker for a variety of carcinomas. Interestingly, EpCAM is explored as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f1704f7c0e6ee1eaabc1dedaa2f00fd
https://doi.org/10.1093/carcin/bgq187
https://doi.org/10.1093/carcin/bgq187
Autor:
Michael Kokkinidis, Gregor Meiss, Arūnas Šilanskas, T. M. Geel, Lou F. M. H. de Leij, Bernardina T. F. van der Gun, Alfred Pingoud, Marcel H. J. Ruiters, Marianne G. Rots, Pamela M.J. McLaughlin, Mindaugas Zaremba, Bart-Jan Kroesen
Publikováno v:
Experimental Cell Research, 315(15), 2487-2495. HANLEY & BELFUS-ELSEVIER INC
TRAIL induced apoptosis of tumor cells is currently entering phase II clinical settings, despite the fact that not all tumor types are sensitive to TRAIL. TRAIL resistance in ovarian carcinomas can be caused by a blockade upstream of the caspase 3 si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321ccfd8b43fbad94b037732142fe90c
https://doi.org/10.1016/j.yexcr.2009.06.011
https://doi.org/10.1016/j.yexcr.2009.06.011
Autor:
Edwin Bremer, Wijnand Helfrich, Douwe F. Samplonius, Lou F. M. H. de Leij, Marco de Bruyn, Theo Bijma, Bram ten Cate
Publikováno v:
Journal of Molecular Medicine, 86(8), 909-924. SPRINGER HEIDELBERG
Journal of Molecular Medicine (Berlin, Germany)
Journal of Molecular Medicine (Berlin, Germany)
Previously, we have shown that epidermal growth factor receptor (EGFR)-selective delivery of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL), by genetic fusion to antibody fragment scFv425, enhances the tumor-selective pro-ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ddfca94443f5b09587699f1f016b12e
https://doi.org/10.1007/s00109-008-0348-9
https://doi.org/10.1007/s00109-008-0348-9
Autor:
Lou F. M. H. de Leij, Antal Kiss, Amélie Monami, Pamela M.J. McLaughlin, Bernardina T. F. van der Gun, Marcel H. J. Ruiters, Elmar Weinhold, Reinhold Wasserkort, Tamás Raskó, Krystyna Ślaska-Kiss, Marianne G. Rots, Rene Cortese, Albert Jeltsch
Publikováno v:
International Journal of Cancer. 123:484-489
The epithelial cell adhesion molecule (EpCAM) is expressed at high levels on the surface of most carcinoma cells. SiRNA silencing of EpCAM expression leads to reduced metastatic potential of tumor cells demonstrating its importance in oncogenesis and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::477e651a8c3cb80bc51f4abca90db6e8
https://doi.org/10.1002/ijc.23476
https://doi.org/10.1002/ijc.23476
Autor:
Lou F. M. H. de Leij, Marjolijn N. Lub-de Hooge, Evert van Garderen, Pamela M.J. McLaughlin, Jos G. W. Kosterink, Jacoba van Zanten, Harry H. Hendrikse, Martin C. Harmsen
Publikováno v:
Journal of Immunology, 179(2), 1362-1368. AMER ASSOC IMMUNOLOGISTS
The human pancarcinoma-associated epithelial cell adhesion molecule (EpCAM) (EGP-2, CO17-1A) is a well-known target for carcinoma-directed immunotherapy. Mouse-derived mAbs directed to EpCAM have been used to treat colon carcinoma patients showing we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b11af3d7a884bb6cb28a02e311cfe6a2
https://doi.org/10.4049/jimmunol.179.2.1362
https://doi.org/10.4049/jimmunol.179.2.1362
Publikováno v:
TRENDS IN MOLECULAR MEDICINE. 12(8):382-393
Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade. In addition, recent reports have indicated the therapeutic potential of physiological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ea4f01f17f8f187676742bf63e3d22
https://hdl.handle.net/11370/346cb422-d97c-4fc1-ab17-ad4c8f6c43eb
https://hdl.handle.net/11370/346cb422-d97c-4fc1-ab17-ad4c8f6c43eb
Publikováno v:
Blood, 107(7), 2863-2870. AMER SOC HEMATOLOGY
Agonistic anti-Fas antibodies and multimeric recombinant Fas ligand (FasL) preparations show high tumoricidal activity against leukemic cells, but are unsuitable for clinical application due to unacceptable systemic toxicity. Consequently, new antile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d310431e0c31434b749206c0216f240f
https://hdl.handle.net/11370/26ed483e-3e5e-4f89-9135-ddc90aeac865
https://hdl.handle.net/11370/26ed483e-3e5e-4f89-9135-ddc90aeac865
Autor:
Wijnand Helfrich, Bart-Jan Kroesen, Douwe F. Samplonius, Linda van Genne, Martin Gramatzki, Georg H. Fey, Lou F. M. H. de Leij, Matthias Peipp, Edwin Bremer
Publikováno v:
Cancer Research. 65:3380-3388
Current treatment of human T-cell leukemia and lymphoma is predominantly limited to conventional cytotoxic therapy and is associated with limited therapeutic response and significant morbidity. Therefore, more potent and leukemia-specific therapies w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a2447518bb54568bff369d8a8b140c
https://doi.org/10.1158/0008-5472.can-04-2756
https://doi.org/10.1158/0008-5472.can-04-2756
Autor:
Sander M. Botter, Robbert J. Kok, Astrid J. Schraa, Dirk K. F. Meijer, Grietje Molema, Lou F. M. H. de Leij, Sebo Withoff
Publikováno v:
International Journal of Cancer, 112(2), 279-285. Wiley
To redirect the lytic activity of cytotoxic T lymphocytes (CTL) toward tumor vascular endothelial cells, we prepared bifunctional proteins with specificity for both alphavbeta3 and CD3. Monocyclic RGD peptides (cRGDfK) were covalently coupled to an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb0d30ce03adda3f158d4a45b8c27d0
https://research.rug.nl/en/publications/7f510584-ca7b-4242-ac92-ede4981d0a6a
https://research.rug.nl/en/publications/7f510584-ca7b-4242-ac92-ede4981d0a6a
Autor:
Lou F. M. H. de Leij, Wijnand Helfrich, Martin C. Harmsen, Bart-Jan Kroesen, Peter Terpstra, W. H. A. Dokter, Marcel H. J. Ruiters, Pamela M.J. McLaughlin, Monika Trzpis
Publikováno v:
Cancer Gene Therapy, 11(9), 603-612. Nature Publishing Group
EGP-2, also known as Ep-CAM, is expressed at high levels on the surface of most carcinomas and is therefore considered an attractive target for anticancer strategies. To explore the mechanisms regulating the expression of EGP-2, sequences 3.4 kb upst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bf43726c53e55d12b3662e369db269c
https://doi.org/10.1038/sj.cgt.7700725
https://doi.org/10.1038/sj.cgt.7700725